Gazeta Buenos Aires - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
RBGPF -4.07% 76 $
CMSD 0.37% 24.38 $
JRI 1.29% 13.95 $
CMSC -0.21% 24.05 $
RELX 1.91% 46.11 $
BCC -0.04% 71 $
GSK 0.48% 44.12 $
SCS 0.72% 16.67 $
NGG -0.44% 76.61 $
BTI -0.9% 51.16 $
RYCEF 0.07% 15 $
RIO 1.76% 69.24 $
VOD -0.09% 11.66 $
BCE -1.68% 23.86 $
AZN -0.98% 83.87 $
BP 0.27% 33.22 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

F.A.Correa--GBA